International journal of clinical practice
-
Int. J. Clin. Pract. · May 2021
Randomized Controlled TrialVibegron Improves Quality-of-Life Measures in Patients With Overactive Bladder: Patient-Reported Outcomes From the EMPOWUR Study.
Quality of life (QOL) can be significantly impacted by symptoms of overactive bladder (OAB). Vibegron is a highly selective β3 -adrenergic receptor agonist that showed efficacy in treatment of symptoms of OAB in the randomised, double-blind, placebo- and active-controlled phase 3 EMPOWUR trial. Here we report patient-reported QOL outcomes from the EMPOWUR trial. ⋯ ClinicalTrials.gov identifier number NCT03492281.